Submitted by bel2021 on June 27, 2018 - 10:22am
| Title | Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required. |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Xue Y, Lito P |
| Journal | Clin Cancer Res |
| Volume | 23 |
| Issue | 6 |
| Pagination | 1365-1367 |
| Date Published | 2017 Mar 15 |
| ISSN | 1078-0432 |
| Keywords | Apoptosis, Cell Proliferation, Humans, Lung Neoplasms, MAP Kinase Signaling System, Protein Kinase Inhibitors, Proto-Oncogene Proteins p21(ras) |
| Abstract | The ERK signaling pathway is one of the most commonly deregulated pathways in cancer. Assays that accurately measure ERK signaling output in clinical specimens would be extremely helpful not only in determining the pharmacodynamic effects of drug treatment but also in selecting those patients most likely to respond to therapy. . |
| DOI | 10.1158/1078-0432.CCR-16-2576 |
| Alternate Journal | Clin. Cancer Res. |
| PubMed ID | 27923842 |